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A B S T R A C T
Background
Asthma is a chronic respiratory condition that affects over 300 million adults and children worldwide. It is characterised by wheeze,
cough, chest tightness, and shortness of breath. Symptoms typically are intermittent and may worsen over a short time, leading to an
exacerbation. Asthma exacerbations can be serious, leading to hospitalisation or even death in rare cases. Exacerbations may be treated
by increasing an individual’s usual medication and providing additional medication, such as oral steroids. Although antibiotics are
sometimes included in the treatment regimen, bacterial infections are thought to be responsible for only a minority of exacerbations,
and current guidance states that antibiotics should be reserved for cases in which clear signs, symptoms, or laboratory test results are
suggestive of bacterial infection.
Objectives
To determine the efficacy and safety of antibiotics in the treatment of asthma exacerbations.
Search methods
We searched the Cochrane Airways Trials Register, which contains records compiled from multiple electronic and handsearched
resources. We also searched trial registries and reference lists of primary studies. We conducted the most recent search in October 2017.
Selection criteria
We included studies comparing antibiotic therapy for asthma exacerbations in adults or children versus placebo or usual care not
involving an antibiotic. We allowed studies including any type of antibiotic, any dose, and any duration, providing the aim was to
treat the exacerbation. We included parallel studies of any duration conducted in any setting and planned to include cluster trials. We
excluded cross-over trials. We included studies reported as full-text articles, those published as abstracts only, and unpublished data.
Data collection and analysis
At least two review authors screened the search results for eligible studies. We extracted outcome data, assessed risk of bias in duplicate,
and resolved discrepancies by involving another review author. We analysed dichotomous data as odds ratios (ORs) or risk differences
(RDs), and continuous data as mean differences (MDs), all with a fixed-effect model. We described skewed data narratively. We graded
the results and presented evidence in ’Summary of findings’ tables for each comparison. Primary outcomes were intensive care unit/
high dependence unit (ICU/HDU) admission, duration of symptoms/exacerbations, and all adverse events. Seconday outcomes were
mortality, length of hospital admission, relapse after index presentation, and peak expiratory flow rate (PEFR).
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Main results
Six studies met our inclusion criteria and included a total of 681 adults and children with exacerbations of asthma. Mean age in the
three studies in adults ranged from 36.2 to 41.2 years. The three studies in children applied varied inclusion criteria, ranging from one
to 18 years of age. Five studies explicitly excluded participants with obvious signs and symptoms of bacterial infection (i.e. those clearly
meeting current guidance to receive antibiotics). Four studies investigated macrolide antibiotics, and two studies investigated penicillin
(amoxicillin and ampicillin) antibiotics; both studies using penicillinwere conducted over 35 years ago. Five studies compared antibiotics
versus placebo, and one was open-label. Study follow-up ranged from one to twelve weeks. Trials were of varied methodological quality,
and we were able to perform only limited meta-analysis.
None of the included trials reported ICU/HDU admission, although one participant in the placebo group of a study including children
with status asthmaticus experienced a respiratory arrest and was ventilated. Four studies reported asthma symptoms, but we were able
to combine results for only two macrolide studies of 416 participants; the MD in diary card symptom score was -0.34 (95% confidence
interval (CI) -0.60 to -0.08), with lower scores (on a 7 point scale) denoting improved symptoms. Two macrolide studies reported
symptom-free days. One study of 255 adults authors reported the percentage of symptom-free days at 10 days as 16% in the antibiotic
group and 8% in the placebo group. In a further study of 40 children study authors reported significantly more symptom-free days
at all time points in the antibiotic group compared with the usual care group. The same study reported the duration in days of the
index asthma exacerbation, again favouring the antibiotic group. One study of a penicillin including 69 participants reported asthma
symptoms at hospital discharge; the between-group difference for both studies was reported as non-significant.
We combined data for serious adverse events from three studies involving 502 participants, but events were rare; the three trials reported
only 10 events: five in the antibiotic group and five in the placebo group. We combined data for all adverse events (AEs) from three
studies, but the effect estimate is imprecise (OR 0.99, 95% CI 0.69 to 1.43). No deaths were reported in any of the included studies.
Two studies investigating penicillins reported admission duration; neither study reported a between-group difference. In one study
(263 participants) of macrolides, two participants in each arm were reported as experiencing a relapse, defined as a further exacerbation,
by the six-week time points. We combined PEFR endpoint results at 10 days for two macrolide studies; the result favoured antibiotics
over placebo (MD 23.42 L/min, 95% CI 5.23 to 41.60). One study in children reported the maximum peak flow recorded during the
follow-up period, favouring the clarithromycin group, but the confidence interval includes no difference (MD 38.80, 95% CI -11.19
to 88.79).
Grading of outcomes ranged from moderate to very low quality, with quality of outcomes downgraded for suspicion of publication
bias, indirectness, imprecision, and poor methodological quality of studies.
Authors’ conclusions
We found limited evidence that antibiotics given at the time of an asthma exacerbation may improve symptoms and PEFR at follow-
up compared with standard care or placebo. However, findings were inconsistent across the six heterogeneous studies included, two
of the studies were conducted over 30 years ago and most of the participants included in this review were recruited from emergency
departments, limiting the applicability of findings to this population. Therefore we have limited confidence in the results. We found
insufficient evidence about several patient-important outcomes (e.g. hospital admission) to form conclusions. We were unable to rule
out a difference between groups in terms of all adverse events, but serious adverse events were rare.
P L A I N L A N G U A G E S U M M A R Y
Are antibiotics a safe and effective additional treatment for asthma exacerbations?
Background to the question
Asthma is a common long-term breathing condition that affects adults and children worldwide. Individuals may experience short-term
worsening of their symptoms, often known as exacerbations (or asthma attacks). Exacerbations are usually treated by stepping up a
person’s medication (e.g. giving steroid tablets for a few days). Sometimes exacerbations can be triggered by infections such as viruses.
Occasionally, a bacterial infection in the lungs or airways might cause an exacerbation. Symptoms of a bacterial infection include
crackles on the chest, fever, and coughing up large volumes of discoloured sputum. Bacterial infections can be confirmed by laboratory
tests, for example, blood tests; however, these are not always available in primary care (at the GP). Bacterial infections may require
treatment with antibiotics.
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In this review, we wanted to find out whether or not antibiotics are helpful and safe for people having asthma exacerbations. Part of
the motivation for this review is a concern that antibiotics may be over-prescribed for people with asthma exacerbations.
Study characteristics
We looked for studies that compared a group of people given any type or dose of antibiotic with a group of people not given an
antibiotic for an exacerbation. We included only studies in which it was decided by chance who would get an antibiotic. We included
studies in adults and children carried out at any time and anywhere in the world.
Key results
We found six studies that included 681 adults and children with asthma. Two of these studies were carried out over 35 years ago.
Overall, we found a small amount of evidence suggesting that antibiotics may improve symptoms and breathing test results compared
with no antibiotic. We are not very sure about these results because only a small number of studies and people were included in our
review. One of our primary outcomes - admission to intensive care unit/high dependence unit (ICU/HDU) - was not reported.
We also cannot be sure if people given antibiotics have more or fewer adverse events (side effects). Only 10 people (5 given antibiotics
and 5 given placebo/no antibiotic) out of 502 had a serious adverse event.
We did not find much evidence about other important outcomes, such as admission to hospital or another exacerbation during the
study follow-up period.
The most recent study found it difficult to recruit people with asthma because so many of them had already been given an antibiotic
and so could not take part.
Quality of the evidence
Overall, we have low confidence in the evidence presented in this review. We think it is possible that some studies of antibiotics for
asthma exacerbations have been carried out but not published because we were able to find so few studies about such an important
question. We were also worried about how well study findings apply to all people with asthma attacks because most of the studies that
we found recruited only people in hospitals and emergency departments. Also, two of the studies were old, and asthma treatment has
changed a lot in 30 years. Because we found only a few studies, in some cases we cannot tell if antibiotics are better than, worse than,
or the same as no antibiotic. Finally, we had some concerns about the ways in which studies were carried out, for example, in one
study both patients and study staff knew who was getting an antibiotic and who was not; this might have affected how patients or staff
behaved.
Conclusions
We found very limited evidence that antibiotics may help people having asthma attacks, and we are still very unsure. In particular, we
did not find much information about important outcomes such as hospital admissions or side effects. However, serious side effects
were very rare in the studies that we found.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antibiotics compared to placebo/usual care for acute asthma
Patient or population: acute asthma exacerbat ion
Setting: emergency department
Intervention: ant ibiot ics
Comparison: placebo/ usual care
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo/
usual care
Risk with antibiotics
ICU/ HDU admission -
not reported
- - - - - One respiratory arrest
in the placebo group
in Shapiro 1974. No
other studies reported
this outcome
Symptom score at 10
days.
Measured on a 7-point
scale (0 to 6) ; lower
score denotes fewer
symptoms
Mean symptom score
at 10 days ranged f rom
2 to 2.20 points
MD 0.34 points lower
(0.60 lower to 0.08
lower)
- (2 RCTs) ⊕⊕⊕©a,d
MODERATE
All adverse events 42 per 100 41 per 100
(33 to 50)
OR 0.99
(0.69 to 1.43)
506
(3 RCTs)
⊕⊕©©
LOWb,c,d,e,f
2 studies in adults and
1 small old study in chil-
dren with status asth-
maticus
Serious adverse events
Durat ion 3 days to 3
weeks
2 per 100 2 per 100
(0 to 45)
RD 0.00
(-0.03 to 0.03)
502
(3 RCTs)
⊕⊕©©
LOWa,d,g,
Anticipated absolute
ef fects were calculated
using the f igures in
Figure 1. This is a re-
presentat ion of the re-
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sults, but to 4 dp, which
allows the calculat ion
to be done
Mortality - not reported - - - - - No deaths were re-
ported in any of the
studies
Length of hospital stay,
days
Mean length of hospital
stay was 2.6 days
MD 0.1 days lower
(0.53 lower to 0.33
higher)
- 43
(1 RCT)
⊕©©©
VERY LOWd,h,I,j
1 study reported me-
dians and IQRs and
found no signif icant dif -
ferences, although data
were skewed
Relapse af ter index pre-
sentat ion - not reported
- - - - -
PEFR (GIV)
Durat ion 10 days
Mean PEFR (GIV)
ranged f rom 19.6 to 26.
9 L/ m in (mean dif fer-
ence f rom baseline)
MD 23.42 L/ min (mean
dif ference f rom base-
line) higher
(5.23 higher to 41.6
higher)
- 469
(2 RCTs)
⊕⊕⊕©
MODERATEa,d,
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; DP: decimal places; GIV: generic inverse variance; HDU: high dependency unit ; ICU: intensive care unit ; IQR: interquart ile range; MD: mean dif ference;
OR: odds rat io; PEFR: peak expiratory f low rate; RCT: randomised controlled trial; RD: risk dif f erence; RR: risk rat io
GRADE Working Group grades of evidence.
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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a -1 indirectness. Studies most ly recruited f rom hospital or emergency department. Therefore this review may represent more
severe exacerbat ions and does not apply to people attending the GP and request ing ant ibiot ics. The review does not apply
to people who have already received a course of ant ibiot ics.
bNo downgrade for risk of bias. One small study excluded 6 part icipants post hoc, but excluding this study f rom the meta-
analysis did not af fect the results.
cNo downgrade. I2 = 0. Dif ferent ant ibiot ics were given in each study.
dNo downgrade. Only six RCTs have been published on ant ibiot ics for asthma exacerbat ion. This strongly suggests that
unpublished data exist or that clinical trials are seriously lacking for this common intervent ion.
e-1 imprecision. Conf idence intervals include the possibility of important benef it and risk of harm.
f -1 indirectness. Studies most ly recruited f rom hospital or emergency department. Therefore this review may represent more
severe exacerbat ions and does not apply to people attending the GP and request ing ant ibiot ics. The review does not apply to
people who have already received a course of ant ibiot ics. One small study recruited children with status asthmaticus in 1974,
when asthma management was dif ferent.
g-1 imprecision. Few events.
h-1 risk of bias. Study before good report ing standards introduced. Concerns over study, which excluded six part icipants, and
it is not clear f rom which arm they were excluded.
i -1 indirectness. Part icipants were all children with status asthmaticus, and the study was conducted before current asthma
management had been introduced (e.g. they all received IV adrenaline).
j -1 imprecision. One small study was included.
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Figure 1. Forest plot of comparison: 1 Antibiotics versus placebo/usual care, outcome: 1.3 Serious adverse
events.
B A C K G R O U N D
Description of the condition
Asthma is a common chronic, inflammatory condition that affects
the airways. It has been estimated that more than 300 million peo-
ple are affected by asthma worldwide (GAN 2014). The predom-
inant symptom is wheeze, but people with asthma also experience
cough, chest tightness, and shortness of breath. There is variation
in the severity of symptoms, and typically symptoms are worse at
night and in the early morning (GINA 2017). Asthma can be a se-
riously debilitating condition for adults and children and remains
an important cause of mortality. However, the inflammatory air-
way changes that occur in asthma generally are very responsive to
treatment and are reversible. Current first-line treatment recom-
mendations consist of controller (inhaled corticosteroids (ICSs)
with or without long-acting beta2-agonists (LABAs)) and reliever
medications (BTS/SIGN 2016).
An expert group proposed the following definition for an asthma
exacerbation: “a worsening of asthma requiring the use of sys-
temic corticosteroids to prevent a serious outcome” (Fuhlbrigge
2012). This statement equates an exacerbation to both worsening
of symptoms and the subsequent need for treatment beyond the
patient’s routine medication. Further, exacerbations can be classi-
fied by their severity using a combination of patient history, exam-
ination findings, and vital signs (BTS/SIGN 2016). Exacerbations
of asthma are generally acute with multiple possible underlying
causes. Most exacerbations are likely to be multi-factorial, with
viral respiratory tract infections implicated in many cases (Jackson
2011). Only a minority of asthma exacerbations are thought to be
triggered by bacteria, although evidence is somewhat limited and
conflicting (Papadopoulos 2011).
Exacerbations of asthma can be severe and may require urgent
treatment. If the exacerbation is severe, guidelines recommend the
use of inhaled short-acting beta2-agonists (SABAs), systemic corti-
costeroid treatment (either oral or intravenous), and ipratropium
bromide, and, in some cases, magnesium sulphate with supple-
mentary oxygen for patients who are hypoxaemic. Antibiotics are
recommended only when clear signs, symptoms, or laboratory test
results are suggestive of bacterial infection (BTS/SIGN 2016).
Description of the intervention
“Antibiotics are a type of antimicrobial [that is] used in the
treatment or prevention of bacterial infections” (Wikipedia).
Macrolides are a class of antibiotic that also displays anti-inflam-
matory properties, which may be of additional benefit in people
with asthma.
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The intervention under review is the administration of antibiotic
agents by any means (e.g. intravenously (IV), orally) to patients
who present to a healthcare provider with a diagnosis of an asthma
exacerbation, in addition to any other treatment they might re-
ceive as part of their care. Antibiotics may be administered or pre-
scribed in a primary care setting, if the exacerbation was not se-
vere enough to warrant immediate hospital admission, or in an
emergency department (ED) or inpatient setting in the context
of a more severe exacerbation. The typical duration of antibiotic
treatment for respiratory tract infection varies fromfive to ten days
(Public Health England). Side effects are likely to be antibiotic
specific and range from fairly common and mild (e.g. nausea) to
rare and serious (e.g. anaphylaxis) (BNF).
How the intervention might work
Antibiotics act against bacteria and work through a bactericidal
or bacteriostatic mechanism of action, either of which assists the
body in clearing a bacterial infection (Kohanski 2010). If a bac-
terial infection is responsible for the exacerbation of asthma, then
administration of an appropriate antibioticmay lead to a reduction
in symptoms and faster recovery. Bacterial infections with atypical
bacterial organisms such as Mycoplasma pneumoniae and Chlamy-
dophila pneumoniae have been associated with acute exacerbations
(Blasi 2007). Furthermore, a case has been made for the use of
macrolides and potentially ketolides in acute exacerbations be-
cause of their concurrent anti-inflammatory effects (Rollins 2010).
However, in a large majority of cases, bacterial infection is not
thought to be the underlying cause of the acute exacerbation of
asthma; in these cases, the patient should derive little benefit from
the administration of antibiotics (Papadopoulos 2011). Moreover,
bacterial immunity to antibiotics is an increasing problem and can
reduce the efficacy of antibiotic treatment for bacterial infection
(Davies 2011).
Why it is important to do this review
Current guidance is clear that for people who present with an acute
asthma exacerbation, use of antibiotics should not be routine, and
that instead, antibiotics should be prescribed only if the patient’s
signs and symptoms, such as fever and purulent sputum, for exam-
ple, suggest that a bacterial infection is present (BTS/SIGN 2016;
Longmore 2014). The unnecessary use of antibiotics puts the pa-
tient at risk for antibiotic-related adverse events and increases the
probability of increasing antibiotic resistance - a global concern
(Davies 2011).
Evidence suggests that a significant number of clinicians are pre-
scribing antibiotics farmore widely for patients with an asthma ex-
acerbation than just for thosewhose presentation suggests that they
have a bacterial infection (Kozyrskyj 2006; Paul 2011; Vanderweil
2008). The apparent gulf between guidelines and actual clinical
practice, the large numbers of patients treated with antibiotics for
acute exacerbations of asthma, and the growing necessity of careful
antibiotic stewardship, as well as cost considerations, all highlight
the importance of providing a clear overview of the best available
evidence on use of antibiotics for acute exacerbations of asthma.
This review aims to clarify the evidence around use of antibiotics
in patients who present with an acute exacerbation of asthma. It is
an update of a previous Cochrane review that was first published
in 2001 and was most recently updated in 2005 (Graham 2001).
To the best of our knowledge, no other, more recent reviews have
examined this topic.
O B J E C T I V E S
To determine the efficacy and safety of antibiotics in the treatment
of asthma exacerbations.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) that were in-
dividually randomised in design. Cluster-randomised trials were
eligible for inclusion, but we did not identify any that met our
inclusion criteria. We included studies reported in full text, studies
published as an abstract only, and unpublished data. We excluded
cross-over trials.
Types of participants
We included studies that recruited children and adults (aged 18
years or over) who presented to the emergency department, pri-
mary care, outpatient clinics, or inpatient wards with an asthma
exacerbation. We included studies that involved inpatients (who
had been admitted for their asthma exacerbation) and outpatients.
When studies included participants from more than one setting,
we included data from relevant settings if reported separately. We
excluded studies that recruited participants with other respiratory
diagnoses including pneumonia (confirmed by X-ray or clinically
diagnosed), chronic obstructive pulmonary disease (COPD), and
bronchiectasis.
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Types of interventions
We included studies comparing antibiotics with placebo or stan-
dard care, when standard care did not include an antibiotic. We
included studies using intravenous or oral antibiotics, given at
any dose and for any duration of treatment. Any co-interven-
tions were permitted, when they were not part of the randomised
treatment (e.g. systemic steroids, inhaled steroids, long- or short-
acting beta2-agonists; ipratropium bromide, magnesium prepara-
tions). We excluded studies of prophylactic antibiotics (i.e. not
commenced specifically for treatment of an exacerbation).
Types of outcome measures
Primary outcomes
1. Intensive care unit/high dependence unit (ICU/HDU)
admission
2. Duration of symptoms/exacerbation (as measured by
trialists using, for example, diary cards, symptom scores, and
assessments of the time taken to return to normal activities)
3. All adverse events/side effects
Secondary outcomes
1. Mortality
2. Length of hospital admission
3. Relapse after index presentation (as defined by trialists, for
example, the need for (further) antibiotics, steroids, admission,
or unscheduled healthcare visits)
4. Peak expiratory flow rate (PEFR) (change from baseline
preferred)
Reporting in the study one or more of the outcomes listed here is
not an inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
We identified studies from the Cochrane Airways Trials Register,
which is maintained by the Information Specialist for the Group.
The Cochrane Airways Trials Register contains studies identified
from several sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL) through the Cochrane Register
of Studies Online (crso.cochrane.org).
2. Weekly searches of MEDLINE Ovid SP 1946 to date.
3. Weekly searches of Embase Ovid SP 1974 to date.
4. Monthly searches of PsycINFO Ovid SP 1967 to date.
5. Monthly searches of Cumulative Index to Nursing and
Allied Health Literature (CINAHL) EBSCO 1937 to date.
6. Monthly searches of Allied and Complementary Medicine
(AMED) EBSCO.
7. Handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. Details
of these strategies, as well as a list of handsearched conference pro-
ceedings, are provided in Appendix 1. See Appendix 2 for search
terms used to identify studies for this review.
We searched the following trials registries.
1. US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov).
2. World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch).
We searched the Cochrane Airways Trials Register and additional
sources from inception to October 2017, with no restriction on
language of publication.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references. We searched relevant manufac-
turers’ websites for study information.
We searched for errata or retractions from included studies pub-
lished in full text on PubMed on 10 November 2017.
Data collection and analysis
Selection of studies
Three review authors (of BS, SW, RN, and ED) independently
screened titles and abstracts of the search results and coded them
as ’retrieve’ (eligible or potentially eligible/unclear) or ’do not re-
trieve’.We retrieved the full-text study reports of all potentially eli-
gible studies, and three review authors (BS, SW, and RN) indepen-
dently screened them for inclusion, recording reasons for exclusion
of ineligible studies. We resolved disagreements through discus-
sion. We identified and excluded duplicates and collated multiple
reports of the same study, so that each study, rather than each re-
port, is the unit of interest in the review. We recorded the selection
process in sufficient detail to complete a PRISMA flow diagram
and ’Characteristics of excluded studies’ table (Moher 2009).
Data extraction and management
We used a data collection form that had been piloted on at least
one study in the review to record study characteristics and outcome
data. Two review authors (BS and SW) extracted the following
study characteristics from included studies.
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1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected and time points reported.
5. Notes: funding for studies and notable conflicts of interest
of trial authors.
Three review authors (BS, SW, and RN) then independently ex-
tracted outcome data from included studies. We noted in the
’Characteristics of included studies’ table if outcome data were not
reported in a usable way. We resolved disagreements by reaching
consensus or by involving a third person (Chris Cates, Statistical
Editor). One review author (RN) transferred data into the Re-
view Manager file (Review Manager (RevMan)). We then double-
checked that data had been entered correctly by comparing data
presented in the systematic review with data provided in the study
reports. A second review author (RN) spot-checked study charac-
teristics for accuracy against the study report.
Assessment of risk of bias in included studies
Two review authors (BS and SW) assessed risk of bias indepen-
dently for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved disagreements through discussion and consultation
with another review author (RN). We assessed risk of bias accord-
ing to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We judged each potential source of bias as presenting high, low, or
unclear risk and provided a quote from the study report together
with a justification for our judgement in the ’Risk of bias’ table.We
then summarised risk of bias judgements across different studies
for each of the domains listed. We considered blinding separately
for different key outcomes when necessary (e.g. for unblinded out-
come assessment, risk of bias for all-cause mortality may be very
different than for a patient-reported pain scale). When informa-
tion on risk of bias relates to unpublished data or correspondence
with a trialist, we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for studies that contributed to that outcome
Measures of treatment effect
We analysed dichotomous data as odds ratios (ORs) or risk differ-
ences (RDs) when events were rare. We analysed continuous data
as mean differences (MDs). If data from rating scales were com-
bined in a meta-analysis, we ensured that they were entered with
a consistent direction of effect (e.g. lower scores always indicate
improvement).
We undertook meta-analyses only when this was meaningful, that
is, when treatments, participants, and the underlying clinical ques-
tion were similar enough for pooling to make sense.
We described skewed data narratively (e.g. as medians and in-
terquartile ranges for each group).
If we had identified single studies that reportedmultiple trial arms,
we planned to include only the relevant arms. If two comparisons
(e.g. drug A vs placebo and drug B vs placebo) had been combined
in the samemeta-analysis, we planned to either combine the active
arms or halve the control group to avoid double-counting.
When adjusted analyses were available (ANOVA or ANCOVA),
we used these as a preference in our meta-analyses. If both change
from baseline and endpoint scores were available for continuous
data, we used change from baseline unless we noted a low corre-
lation between measurements for individuals. If a study reported
outcomes at multiple time points, we used the latest time point
reported.
We used intention-to-treat (ITT) or ’full analysis set’ analyses
when reported (i.e. those for which data had been imputed for
participants who were randomly assigned but did not complete
the study) instead of completer or per-protocol analyses.
Unit of analysis issues
For dichotomous outcomes, we used participants, rather than
events, as the unit of analysis. However, when rate ratios were
reported in a study, we analysed them on this basis. We meta-
analysed data from cluster-RCTs only if available data has been
adjusted (or could be adjusted), to account for the clustering.
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and obtain missing numerical outcome data when
possible (e.g. when a study is identified as an abstract only). When
this was not possible, and the missing data were thought to intro-
duce serious bias, we took this into consideration when determin-
ing the GRADE rating for affected outcomes.
Assessment of heterogeneity
Weused the I² statistic tomeasure heterogeneity among the studies
in each analysis. We did not identify substantial heterogeneity in
our analyses.
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Assessment of reporting biases
If we had been able to pool more than 10 studies, we planned to
create and examine a funnel plot to explore possible small-study
and publication biases.
Data synthesis
’Summary of findings’ table
We created a ’Summary of findings’ table using all pre-specified
outcomes. We used the five GRADE considerations (risk of bias,
consistency of effect, imprecision, indirectness, and publication
bias) to assess the quality of a body of evidence as it relates to
studies that contributed data for the pre-specified outcomes. We
used the methods and recommendations described in Section 8.5
and Chapter 12 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011), along with GRADEpro software
(GRADEpro GDT). We justified all decisions to downgrade the
quality of studies by using footnotes and made comments to aid
the reader’s understanding of the review when necessary.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
1. Adults (aged 18 years) versus children.
2. Antibiotic type (macrolides versus other).
3. Setting: inpatient versus outpatient.
4. C-reactive protein (CRP)-stratified treatment versus non-
CRP-stratified treatment.
We then planned to use the following outcomes in subgroup anal-
yses.
1. ICU/HDU admission.
2. Duration of symptoms/exacerbation.
3. All adverse events/side effects.
We used the formal test for subgroup interactions provided in
Review Manager (Review Manager (RevMan).
Sensitivity analysis
We planned to carry out the following sensitivity analyses while
removing the following from the primary outcome analyses.
1. Excluding open-label trials.
2. Excluding trials at high risk of selection bias.
3. Excluding unpublished data.
4. Comparing results from the fixed-effect model versus
results from the random-effects model.
R E S U L T S
Description of studies
Full details of the conduct and characteristics of each included
study canbe found in theCharacteristics of included studies tables,
and reasons for exclusion when full texts had to be viewed are
given in the Characteristics of excluded studies table.
Results of the search
This review is an update of a previous review (Graham 2001). We
fully revised the protocol including background, PICO (popula-
tion, intervention, comparison, outcomes), and methods and reg-
istered the protocol on PROSPERO (Normansell 2017). There-
fore we ran a new ’all years’ search.
The preliminary searches conducted yielded a total of 429 refer-
ences - 364 from electronic database searches and 67 from records
obtained through searches of clinicaltrials.gov and the World
Health Organization (WHO) trials portal (http://apps.who.int/
trialsearch/).We excludedmost (n = 402) of these references on the
basis of the title and abstract. From these references, we identified
27 studies as potentially relevant. Six studies (for which there were
13 records) met the inclusion criteria for this review (Fonseca-Aten
2006; Graham1982; Johnston 2006; Johnston 2016; Koutsoubari
2012; Shapiro 1974), and we excluded the other 14 (see Excluded
studies section). We have presented a study flow diagram in Figure
2. We conducted the latest search on 17 October 2017.
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Figure 2. Study flow diagram.
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Included studies
Six studies met our inclusion criteria, four of which contributed
data to at least one meta-analysis. These studies included a total
of 681 participants who were randomly assigned to comparisons
of interest in this review. The largest study included 278 partici-
pants (Johnston 2006), and the smallest 40 (Koutsoubari 2012).
The mean total number of participants was 114, and the median
number was 55. Investigators reported all six trials in full peer-
reviewed articles. We present a summary of the characteristics of
included studies in Table 1.
We attempted to contact authors of Fonseca-Aten 2006 for more
information in July 2017 but were unable to make contact with
the named contact person. The lead author of Johnston 2006 and
the trial statistician for Johnston 2016 provided additional details
on request.
Methods
As per our protocol, all included trials were RCTs, which individu-
ally randomised participants to antibiotics versus placebo or usual
care. Five studies had post-treatment follow-up periods ranging
from one to twelve weeks, and only one did not define a follow-
up period (Graham 1982). No study reported a run-in period, as
recruitment was triggered by an unscheduled presentation with
an exacerbation. Outcome data were extracted at the end of an-
tibiotic treatment or at the last time point reported. Two studies
were conducted in the UK (Graham 1982; Johnston 2016), two
in the USA (Fonseca-Aten 2006; Shapiro 1974), one in Greece
(Koutsoubari 2012), and the other (an international study) across
multiple centres (Johnston 2006). Most of these studies recruited
participants from the emergency department, from an urgent care
setting, or when patients were admitted to hospital. One study
recruited via parents bringing their children to them if an exac-
erbation was suspected, before subsequently attending hospital to
confirm (Koutsoubari 2012).
Participants
We included studies involving both adults and children. Three
studies recruited only children (age range 1 to 18, depending on
the specific study (Fonseca-Aten2006; Koutsoubari 2012; Shapiro
1974)), two recruited only adults (age range 17 to 68, and 18 to
55 years; Johnston 2006; Johnston 2016), and one included ado-
lescents and adults (age range 14 to 82; Graham 1982). Two stud-
ies included information on the ethnicity of participants. Most of
those included were of white ethnicity (88.9% for the intervention
arm and 94.6% for the control arm) in Johnston 2006, whilst the
highest proportions of participants were of black ethnicity (68%
and 48%, respectively) in Fonseca-Aten 2006.
All studies included participants experiencing an asthma exacer-
bation, but how this was defined varied across the included stud-
ies. Of note, in Shapiro 1974, participants were given a diagnosis
of “status asthmaticus” (defined as “a lack of response of severe
bronchospasm to three subcutaneous injections of 1:1000 aque-
ous epinephrine given at 15-minute intervals”). Three studies re-
ported the asthma history of participants in the number of years
since diagnosis, and only one reported the severity of asthma of
participants and the severity of the exacerbation (Johnston 2016),
although another also reported the current exacerbation severity
index (Koutsoubari 2012). Both Johnston studies reported the
smoking status and pack-years of participants (Johnston 2006;
Johnston 2016), Koutsoubari 2012 reported the percentage of par-
ticipants exposed to tobacco smoke, and Graham 1982 reported
the percentage of current smokers. It is interesting to note that
Graham 1982 reported the proportion of participants who had
received antibiotic treatment during the week before admission
(24.3% in the treatment arm and 17.6% in the control arm); this
was an exclusion criterion for most of the included studies.
All but one study explicitly excluded participants with a di-
agnosed, or strongly suspected, bacterial infection and those
who had received recent antibiotic therapy (Koutsoubari 2012).
Fonseca-Aten 2006 excluded children with a diagnosis of bacte-
rial infection needing antibiotics. Graham 1982 excluded partic-
ipants whose chest X-rays showed signs of pneumonia. Johnston
2006 excluded participants reporting any antibiotic use within
30 days before enrolment, or with an obvious infection requir-
ing antibiotic treatment. Johnston 2016 excluded participants re-
porting use of oral or systemic antibiotics within 28 days before
enrolment and participants requiring other antibiotic therapy. Fi-
nally, Shapiro 1974 excluded participants with evidence of bac-
terial disease, specifically, any of the following - otitis media, pu-
rulent pharyngitis, or fever - and lobular pulmonary infiltrate on
admission chest X-ray who recently received antibiotics.
Interventions
Four studies investigated macrolide antibiotics, with two tri-
alling clarithromycin (Fonseca-Aten 2006; Koutsoubari 2012),
one azithromycin (Johnston 2016), and one telithromycin (part
of the subgroup of macrolides known as ketolides) (Johnston
2006). The two remaining studies investigated penicillins, specif-
ically, amoxicillin (Graham 1982) and hetacillin (known now as
ampicillin) (Shapiro 1974). All studies compared the antibiotic
of choice against a placebo, apart from Koutsoubari 2012, which
was an open-label study with usual care comparison. Both stud-
ies investigating clarithromycin were carried out in children and
administered the antibiotic at the same dose (15 mg/kg/d). Doses
used in each study are detailed in the summary of included studies
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(Table 1).
Outcomes
Outcomes reported were not consistent across the included stud-
ies. Lung function was the most consistently measured outcome,
as reported by five of the six included studies. Most studies also
reported some measure of participant symptoms at the end of
treatment or follow-up, or time taken for resolution of symptoms.
Both Johnston 2006 and Johnston 2016 used an asthma symptom
score. Graham 1982 and Shapiro 1974 reported duration of symp-
toms. Only half of the included studies reported adverse events,
and only two explicitly reported serious adverse events (Johnston
2006; Johnston 2016).
Funding
Two trials were sponsored by pharmaceutical companies (Fonseca-
Aten 2006; Johnston 2006), two were funded by governmental
agencies (Johnston 2016; Shapiro 1974), and the funding source
for two studies was not reported (Graham 1982; Shapiro 1974).
Excluded studies
We excluded 14 records after full-text assessment. We excluded
11 studies (12 records) with reasons as detailed in Characteristics
of excluded studies. One trial is reported to be ongoing (
NCT02003911). A further study is awaiting classification; this
trial was registered on the EU clinical trials register in 2010, last
refreshed on 20 September 2016, with status currently no longer
recruiting.Wewere unable to identify a linked publication, and no
contact details were given (EUCTR2010-018592-16-DK). Nine
of the excluded studies investigated long-term use of antibiotics
as prophylaxis for asthma rather than as treatment for exacerba-
tions. One study investigated participants with chronic asthma,
and another included participants with asthma-like symptoms,
rather than with confirmed asthma.
Risk of bias in included studies
We noted substantial variation in the levels of risk of bias between
and within the studies included in this review. Moreover, although
we judged few aspects of these studies to have high risk of bias,
we found instances in studies when lack of detail on the precise
methods used by study authors meant that the level of risk of
bias was unclear. Figure 3 provides an overview of our risk of bias
judgements.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We found three studies to have low risk of selection bias (Johnston
2006; Johnston 2016; Koutsoubari 2012), and three to have un-
clear risk (Fonseca-Aten 2006;Graham 1982; Shapiro 1974). This
lack of clarity was due to lack of detail on the exact methods used
by study authors.
Blinding
One study used an open-label design and therefore was at high
risk of performance and detection bias (Koutsoubari 2012). All
the other studies reported that they were double-blinded (i.e. par-
ticipants and personnel), and we considered them to be at low risk
of performance bias. Only two studies provided sufficient detail
on themethod used to blind outcome assessors to indicate low risk
of detection bias (Johnston 2006; Johnston 2016). For the other
three studies, we judged the risk as unclear.
Incomplete outcome data
Studies varied in the level of risk of attrition bias. We judged
Koutsoubari 2012 to be at low risk, as study authors stated that
all randomised participants completed the trial. Two participants
from the placebo group in Graham 1982 dropped out owing to
slow clinical progress, but trialists describe including them in a
sensitivity analysis under worst-case scenario assumptions, which
had no impact on the overall results. We therefore judged this
study to be at low risk.
We judged Shapiro 1974 to be at high risk, as researchers excluded
6 of the 50 participants initially included: three because they de-
veloped signs and symptoms suggesting bacterial disease, and three
because of inadvertent failure to administer the study preparation.
The distribution between study arms of those excluded for sus-
pected bacterial infection and for protocol violations is not re-
ported. As the study was conducted over 40 years ago, we have not
attempted to clarify this with the study authors. We also judged
Fonseca-Aten 2006 to be at high risk, as more than 50% of par-
ticipants did not complete follow-up; however, this study did not
contribute outcome data to the review.
We considered Johnston 2006 to be at low risk of attrition bias for
adverse events; 263 of 270 randomised participants were included
in the safety analysis. Re-inclusion of missing participants under
best-worst case assumptions and worst-best case assumptions had
little impact on the pooled effect estimate for all adverse events
or for serious adverse events. More data for symptom scores and
PEFR were missing (e.g. 240 out of 270 randomised provided day
10 symptom score data, and 253 out of 270 provided day 10 peak
flow readings). We received detailed data tables and the statisti-
cal analysis plan from the lead study author. This confirms that
missing end-point PEFR data were imputed from a previous non-
baseline reading, if available. No baseline readings were carried
forward. For missing domiciliary PEFR measurements, the aver-
age of previous and subsequent readings (if available) was used for
imputation, and again, no baseline readings were carried forward.
A similar approach was used to deal with missing symptom scores
from patient diary cards. Given that we cannot be certain what
impact the entirely missing values may have had on the final effect
estimate, overall we rated this study as having unclear risk of bias.
We judged Johnston 2016 also to be at low risk for bias for adverse
events; correspondence with the trial statistician confirmed that
all randomised participants were included in the safety analysis.
However, as with Johnston 2006, more data for other outcomes
were missing. Twenty per cent of participants missed at least one
study visit, 60 did not provide day 10 symptom score data, and
36 did not provide a day 10 peak flow reading. The trial statisti-
cian confirmed that mixed (multi-level) modelling was used; thus
all available diary records were included in the model, regardless
of availability of the day 10 reading. It is unclear what impact
the entirely missing values may have had on the effect estimates;
therefore, results should be interpreted with caution. Overall, we
judged this trial to be at unclear risk of attrition bias.
Selective reporting
For three studies, the level of risk of reporting bias was unclear.
For one, there was low risk, and for two we judged the risk to be
high.
We judged Fonseca-Aten 2006 to be at high risk of reporting bias.
We were not able to identify a prospective registration or pub-
lished protocol, and we found that not all evaluated outcomes
were reported numerically, for example, “No clinical differences
were demonstrated for clarithromycin therapy vs placebo on visit
3”. Attempts to contact study author teams failed. We also judged
Shapiro 1974 to be at high risk; we found no prospective registra-
tion or protocol and determined that researchers did not evaluate
all outcomes numerically (e.g. graphically displayed only), so we
could not include these data in the meta-analysis.
We judged Graham 1982 to be at unclear risk. Again, we were
not able to identify a published protocol or a prospective registra-
tion, but study authors clearly reported all outcomes described in
the methods section. However, study authors used medians and
ranges and non-parametric tests, so we could not combine data in
meta-analyses. Similarly, we were unable to identify a published
protocol or registration for Koutsoubari 2012, but we found that
study authors clearly reported all outcomes described in the meth-
ods. Study authors used medians and interquartile ranges for non-
normal data, so these were not combined in meta-analyses.
We judged Johnston 2016 to be at low risk of reporting bias; the
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trial was prospectively registered and outcomes were reported as
planned. Of note, the trial team relaxed the inclusion criteria in
an attempt to improve recruitment, but this is unlikely to have
introduced bias.
We judged Johnston 2006 to be at unclear risk of bias because sev-
eral outcomes listed in the prospective trial registration were not
fully reported, including outcomes of interest for this review (i.e.
health status at follow-up (6 weeks); need for additional medica-
tion (e.g. ICS, oral corticosteroid (OCS), bronchodilator); time to
next exacerbation of asthma). The lead study author provided the
following explanation: “the time-to-next-acute-exacerbation and
need for additional medications data were not included because
acquisition of such data in the setting of an acute exacerbation
study, not unexpectedly, was so incomplete that a decision was
taken not to analyse them”.
Other potential sources of bias
In Graham 1982, participants could be included more than once
in the trial, as the episode, rather than the individual, was the
unit of randomisation: 60 patients experienced 71 exacerbations
during the trial. We are unable to determine what effect this had
on the effect estimates reported. We detected baseline imbalance
between arms in Shapiro 1974, including differences in the mean
number of days of wheezing before admission (2.6 in the hetacillin
group and 5.8 in the placebo group).
Effects of interventions
See: Summary of findings for the main comparison Antibiotics
compared to placebo or usual care for exacerbations of asthma
Intensive care unit/high dependency unit admission
Children
One child in the placebo group of Shapiro 1974 experienced res-
piratory arrest shortly after admission and was mechanically ven-
tilated; we assume this child would have received care in an ICU/
HDU setting. Of note, this study was conducted in children with
status asthmaticus. None of the other included studies reported
this outcome.
Duration of symptoms/exacerbation
Nostudies reported on the durationof symptomsor exacerbations,
which was our pre-specified outcome. However, four studies used
different approaches to report asthma symptoms (Graham 1982;
Johnston 2006; Johnston 2016; Koutsoubari 2012).
Adults
Graham 1982 reported a physician’s assessment of asthma symp-
toms at hospital discharge (median duration of admission seven
days in the amoxicillin group and eight days in the placebo group)
on a 4 to 12-point scale (higher score = worse symptoms) with
results presented as medians and ranges. The median (range) score
in the amoxicillin group was 5 (4 to 9), and in the placebo group
4 (4 to 8) (n = 69). The same study reported patients’ assessment
of symptoms at discharge on a visual analogue scale (lower score =
worse symptoms), also as medians and ranges. Themedian (range)
score in the amoxicillin group was 33 (range 0 to 250), and in the
placebo group 28 (0 to 85) (n = 69). The visual analogue scale was
reported to be 10 cm and the results given in millimetres; as the
trial was conducted in 1982, we did not attempt to resolve the dis-
crepancy that the range reported exceeds the scale. The between-
group difference for both scores was reported as non-significant.
Graham 1982 also reported the median and range of numbers of
days to 50% improvement in symptoms as assessed by both physi-
cian and patient. In the amoxicillin group, the median (range)
numbers of days was 3 (1 to 6) for the physician assessment and 3
(2 to 10) in the placebo group. For patients’ assessment, the scores
were 2 (2 to 10) and 2 (2 to 8), respectively.
Participants in Johnston 2006 (a trial of telithromycin) and
Johnston 2016 (a trial of azithromycin) were asked to rate their
own symptoms using modified diary cards on a 7-point scale (0 =
no symptoms, 6 = severe symptoms). We were able to extract data
at 10 days and at six weeks from Johnston 2006, and at 10 days
from Johnston 2016. We chose to combine the 10-day findings
using mean differences. Results favour antibiotics over placebo
(mean difference (MD) -0.34, 95% confidence interval (CI) -0.60
to -0.08; participants = 416; I2= 0%; studies = 2; Analysis 1.1;
moderate-quality evidence). At six weeks, participants in the in-
tervention group of Johnston 2006 still reported lower symptom
scores than those in the control group, but the upper confidence
interval includes no between-group difference (MD -0.2, 95% CI
-0.5 to 0.02; P = 0.066). Johnston 2006 also reported the number
of symptom-free days as a percentage at 10 days (calculated by
dividing the number of days when all symptom scores in the diary
were zero by the number of days for which the patient provided
scores); results favoured telithromycin (16% of days symptom-free
vs 8%; P = 0.006; participants = 255).
Children
Koutsoubari 2012 reported themedian and the interquartile range
(IQR) for symptom-free days at 3, 6, and 12 weeks. At 3 weeks,
the median (IQR) for the clarithromycin group was 16 (1), and
for the control group 12 (2) (n = 40). At 6 weeks, values were
reported as 36 (2) and 29 (3), respectively (n = 40), and by 12
weeks, 78 (2) and 69 (6), respectively (n = 40) (P < 0.0001 at all
three time points). The same study reported the duration in days
of the index asthma exacerbation, also as median and IQR. The
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median (IQR) in the clarithromycin group was 5 (1), and in the
control group 7.5 (1) (n = 40) (P < 0.00001).
All adverse events/side effects
Four studies reported adverse events (Johnston 2006; Johnston
2016; Koutsoubari 2012; Shapiro 1974). We combined data for
all adverse events (AEs) from three studies; the confidence interval
includes both potential harm or benefit of the intervention (odds
ratio (OR) 0.99, 95% CI 0.69 to 1.43; participants = 506; studies
= 3; I2 = 0%; low-quality evidence; Analysis 1.2). Researchers re-
ported no significant difference in the test for subgroup differences
between adults and children.
We also combined data for serious adverse events (SAEs).We were
able to extract data from three studies, and we analysed the result
as a risk difference because events were rare. The pooled result sug-
gests no difference between antibiotic and control, but it should
be noted that only 10 events were reported across the three trials
(five in the antibiotic group and five in the placebo group) (risk
difference (RD) 0.00, 95% CI -0.03 to 0.03; participants = 502;
studies = 3; I2 = 0%; low-quality evidence, Analysis 1.3). Study
results show no significant difference in the test for subgroup dif-
ferences between adults and children.
Adults
Pooled data for the adults subgroup were as follows: OR 1.00,
95% CI 0.69 to 1.45.
Children
Shapiro 1974 also reported ’complications’ after discharge and
noted two in the hetacillin group (one hospitalisation for asthma,
and one participant experienced persistent wheezing) and three in
the placebo group (fever, diarrhoea, and pulmonary infiltrate in
one participants, abdominal discomfort in another, and persistent
wheezing in a third).
For serious adverse events, Koutsoubari 2012 reported that no
participant required hospital admission during the study; as the
definition of a serious adverse event is “death, a life-threatening
adverse event, inpatient hospitalisation or prolongation of existing
hospitalisation”, we assumed that no participant had experienced
an SAE.
Mortality
No deaths were reported in any of the included studies.
Length of hospital admission
Two studies reported admission duration, but we could not com-
bine the results (Graham 1982; Shapiro 1974).
Adults
Graham 1982 reported median (range) duration of admission in
days as 7 (3 to 25) in the amoxicillin group and 8 (3 to 6) in the
placebo group (n = 69; reported as not significantly different).
Children
Shapiro 1974 reported the mean (SD) duration of admission; the
confidence interval includes the possibility of an increase or a
decrease in duration of admission in the hetacillin group (MD -
0.10, 95% CI -0.53 to 0.33; participants = 43; studies = 1; very
low-quality evidence, Analysis 1.4).
Relapse after index presentation
One study reported exacerbations in the follow-up period (
Johnston 2006). Two adults in each arm experienced an exacerba-
tion by the six-week time points (n = 263).
Peak expiratory flow rate
Four studies reported peak expiratory flow rate (PEFR) (Graham
1982; Johnston 2006; Johnston 2016; Koutsoubari 2012).
Adults
We combined endpoint results at 10 days for Johnston 2006 and
Johnston 2016 using generic inverse variance (GIV). The result
favours antibiotics over placebo with the mean difference exceed-
ing the minimal clinically important difference of 18.79 L/min
(Santanello 1999): MD 23.42 L/min, 95% CI 5.23 to 41.60; par-
ticipants = 416; studies = 2; Analysis 1.5. However, the pre-spec-
ified primary outcome in Johnston 2006 was change in domicil-
iary morning PEFR. Based on modelled data, the mean difference
between groups in the change from baseline was reported as 3.6
L/min (95% CI -32.5 to 25.3; P = 0.81).
Children
One study in children reported the maximum peak flow recorded
during the follow-up period (Koutsoubari 2012); results favoured
the clarithromycin group, but the confidence interval includes no
difference (MD 38.80, 95% CI -11.19 to 88.79; participants =
40; studies = 1; Analysis 1.6).
Subgroup and sensitivity analyses
Subgroup analysis
Subgroup analysis was restricted by the small number of trials
identified.
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Adults (aged 18 years) versus children
Data for adults and children were subgrouped throughout and
were reported separately above. Only two meta-analyses pooled
data from adults and children: serious adverse events and all ad-
verse events. No serious events were reported in the one study in
children, and the test for subgroup differences was negative (P =
0.99; I2 = 0%). Similarly for all adverse events, no subgroup dif-
ference was detected (P = 0.80; I2 = 0%).
Antibiotic type (macrolides vs other)
Only one meta-analysis pooled data from two different classes of
antibiotic: all adverse events. We detected no difference between
the two studies investigating a macrolide antibiotic and the one
study investigating a penicillin (P = 0.80; I2 = 0%) (analysis not
shown); however, the one study investigating penicillin was con-
ducted in 1974, and the two investigating macrolides in 2006 and
2016.
Setting: inpatient versus outpatient
Most of the participants included in this review were recruited in
a hospital or emergency department setting. Two trials reported
recruiting some participants from urgent care or primary care cen-
tres but did not present data disaggregated by setting (Johnston
2006; Johnston 2016).
CRP-stratified treatment versus non-CRP-stratified
treatment
None of the included studies reported stratifying treatment by
CRP results.
Sensitivity analysis
Excluding open-label trials
Only one studywas reported to be open-label (Koutsoubari 2012).
This studywas combinedwith other studies in one analysis (serious
adverse events) but did not contribute events; thus its exclusion
has no impact on the effect estimate.
Excluding trials at high risk of selection bias
We did not judge any of the included trials to be at high risk of
selection bias. Three trials were at unclear risk for both random
sequence generation and allocation concealment, but only one trial
contributed to a meta-analysis (Shapiro 1974): all adverse events.
Excluding this trial had minimal impact on the effect estimate
(OR 1.00, 95% CI 0.69 to 1.45; participants = 462; studies = 2;
I2 = 0%; data not shown).
Excluding unpublished data
We did not include any unpublished data in our meta-analyses.
Comparing results from the fixed-effect model versus the
random-effects model
Results show a negligible difference between random-effects and
fixed-effect models.
D I S C U S S I O N
Summary of main results
This review is an update of a previous review (Graham 2001), and
we have run a new ’all years’ search. We fully revised the protocol
including background, PICO (population, intervention, compar-
ison, outcomes), and methods, and registered it on PROSPERO
(Normansell 2017). Six studies met our inclusion criteria, four of
which contributed data to at least one meta-analysis. These studies
included a total of 681 adults and children who were randomly as-
signed to comparisons of interest in this review. Four studies inves-
tigated macrolide antibiotics (Fonseca-Aten 2006; Johnston 2006;
Johnston 2016; Koutsoubari 2012), and two studies investigated
ampicillin and amoxicillin, respectively (Graham 1982; Shapiro
1974); both studies were conducted over 30 years ago. Five stud-
ies compared antibiotics versus placebo, and one was open-label
(Koutsoubari 2012). We were able to perform limited meta-anal-
ysis owing to the small number of trials identified and between-
study heterogeneity.
None of the included trials reported intensive care unit/high de-
pendence unit (ICU/HDU) admission, although one participant
in the placebo group of Shapiro 1974 (a study including children
with status asthmaticus) experienced respiratory arrest shortly after
admission and was mechanically ventilated. None of the included
studies reported our outcome of interest - duration of symptoms.
Studies provided some data on symptom scores, and four stud-
ies reported some measure of symptom-free days. Overall these
favoured antibiotics, but measures show ambiguity.
No deaths were reported in any of the included studies. Four
studies reported adverse events, and we were able to combine data
for serious adverse events from three studies, but these events were
rare; only 10 events were reported across the three trials (five in the
antibiotic group and five in the placebo group; 502 participants):
risk difference (RD) 0.00, 95% confidence interval (CI) -0.03 to
0.03. We combined data for all adverse events (AEs) from three
studies; the confidence interval includes potential harm or benefit
of the intervention: odds ratio (OR) 0.99, 95% CI 0.69 to 1.43.
One study reported exacerbations in the follow-up period (
Johnston 2006). Two participants in each arm were reported as
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experiencing an exacerbation within six weeks (n = 263). Four
studies reported peak expiratory flow rate (PEFR). We combined
endpoint results at 10 days for Johnston 2006 and Johnston 2016,
and results favoured antibiotics over placebo, with the mean dif-
ference (MD) exceeding the minimal clinically important differ-
ence: mean difference (MD) 23.42 L/min, 95% CI 5.23 to 41.60.
One study in children reported the maximum peak flow recorded
during the follow-up period (Koutsoubari 2012); results favoured
the clarithromycin group, but the confidence interval included no
difference: MD 38.80, 95% CI -11.19 to 88.79. All three studies
that reported PEFR used macrolide antibiotics - therefore the re-
duction in peak flow could have been due at least in part to the
anti-inflammatory properties.
Wewere able to performonly very limited subgroup and sensitivity
analyses owing to the small number of trials identified, and we
found no evidence of important effect modification according to
age or class of antibiotic, although this cannot be ruled out.
Overall completeness and applicability of
evidence
The evidence presented is considered incomplete because of the
small number of relevant trials identified, between-study hetero-
geneity limiting meta-analysis, and the age of two of the six studies
- one randomised controlled trial (RCT) was conducted in 1974
(Shapiro 1974), and another in 1982 (Graham 1982). Applicabil-
ity of evidence from RCTs conducted over 30 years ago is ques-
tionable. Shapiro 1974, for example, used a definition of an acute
exacerbation of asthma that diverges from that used in modern
day practice; furthermore reports show differences between the
treatment protocol and current guidelines for the treatment of in-
dividuals with acute exacerbations of asthma. Furthermore, most
participants were recruited at a hospital, rather than in a primary
care setting, and this may limit generalisability to other settings,
for example, primary care.
Only four of the six included studies contributed to the meta-
analysis. A large portion of the data was not presented in the study
papers in a format compatible with the other studies, or simply
was not reported. Fonseca-Aten 2006 included no clinical data
in its study results. Considerable heterogeneity is evident between
the outcomes reported in these studies. This discrepancy between
outcomes made it difficult to carry out much meaningful meta-
analysis, limiting the completeness of presented evidence. We did
not seek to address the benefits or harms of long-term antibiotic
use in asthma; this is the topic of a separate review (Kew 2015).
Five of the six studies included in this review specifically excluded
participants if they received the diagnosis of a bacterial infection,
or if one was strongly suspected. Consequently, application of re-
view findings is limited to patients with an exacerbation of asthma
without signs, symptoms, or investigative findings suggestive of
bacterial infection (i.e. those not meeting current guidance to re-
ceive antibiotics). However, it would be considered unethical to
withhold antibiotics from a patient considered likely to have a
bacterial infection; thus current and future studies are unlikely
to address this question. Furthermore, although included studies
in adults excluded participants with other respiratory comorbidi-
ties, such as chronic obstructive pulmonary disease (COPD) or
“COPD-asthma overlap syndrome” (ACOS), this condition may
be more difficult to diagnose; thus it is possible that the adult trials
included participants with this diagnosis, potentially confounding
study results (Soriano 2003). Although none of the included stud-
ies presented results stratified by smoking history, the two largest
included studies in adults excluded participants with a greater than
10 or 5 pack-year smoking history, respectively (Johnston 2006;
Johnston 2016).
A pertinent observation arising from this review relates to the dif-
ficulty of participant recruitment highlighted in Johnston 2016.
Trialists were able to recruit a total of only 199 participants out
of a total 4582 assessed, with 2044 excluded for receiving prior
antibiotic treatment. For every patient randomised, at least 10 pa-
tients were excluded for this reason. This suggests that use of an-
tibiotics may be widespread in the United Kingdom, possibly con-
trary to current guidelines (BTS/SIGN 2016). Guidelines clearly
state that antibiotics should not be used for routine treatment
of acute asthma exacerbations (BTS/SIGN 2016; GINA 2017).
Researchers have found evidence to suggest high levels of antibi-
otic prescription for acute exacerbations of asthma. In the United
States, one study reported this to be as high as 60% (Lindenauer
2016); similarly a study in China reported that almost 75% of
patients attended the emergency department for an acute exac-
erbation and received an antibiotic (Tang 2013); the equivalent
figure from a study conducted in the United Kingdom was 57%
(Bafadhel 2011). These figures pose a challenge for researchers at-
tempting to carry out studies examining the efficacy and safety of
antibiotics for acute exacerbations of asthma.
A further complication for interpretation is that any modest ben-
efits associated with macrolide use may be the result of anti-in-
flammatory rather than antibacterial properties of this class of an-
tibiotic (Rollins 2010). Head-to-head studies comparing classes of
antibiotics would be of limited use in resolving this uncertainty, as
effects would be confounded by the different spectrum of bacte-
ria against which antibiotics are effective. Had we identified more
studies, we would have had to consider whether pooling older
studies using penicillin antibiotics with more recent studies using
macrolides made clinical sense. However, the only meta-analysis
in which this occurred was that for all adverse events, in which
the two recent Johnston trials using macrolides were pooled with
an older study using ampicillin. The test for subgroup differences
in this meta-analysis is negative but underpowered. Issues of ap-
propriate pooling may become more relevant in future updates of
this review if additional trials are identified.
Finally, it should be noted that none of the patients were in-
cluded on the basis of inflammatory markers such as C-reactive
protein (CRP) or procalcitonin, although evidence suggests that
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these markers were used to beneficial effect to reduce antibiotic
prescription for patients with asthma (Long 2014). Access to tests
to confirm a bacterial infection is not routinely available to all
doctors worldwide, especially in a primary care setting. Moreover,
no studies provided information on costs, and none explored po-
tential issues arising from antibiotic resistance.
Quality of the evidence
Grading of outcomes ranged from moderate to very low quality.
Our confidence was reduced for all outcomes by suspicion of pub-
lication bias; despite the availability of a common treatment for
asthma, we identified only six eligible RCTs, suggesting that un-
published data may exist. However, we were not able to formally
explore this by using a funnel plot because we identified an in-
sufficient number of studies. Our confidence was further reduced
by indirectness; most of the included trials recruited from emer-
gency care settings, limiting applicability to primary care settings,
to which many people with acute exacerbations of asthma initially
present. This problem was further compounded by the most re-
cent trial - Johnston 2016 - which struggled to recruit sufficient
participants as so many people had already received a course of an-
tibiotics at the time they presented to the emergency department
and were therefore excluded. In addition, we downgraded quality
for indirectness owing to the age of two of the six studies. Im-
precision affected both adverse event outcomes (small numbers of
events and few contributing trials) and length of hospital stay. Fi-
nally, we had concerns about risk of bias related to lack of blinding
in outcomes contributed to by Koutsoubari 2012. We were also
concerned about unclear reporting of trial methods for outcomes
contributed to by two older trials; these were conducted at a time
when methodological practice in conducting trials may have been
less rigorous, and when asthma care was different (Graham 1982;
Shapiro 1974).
Potential biases in the review process
We conducted this review in accordance with Cochrane standards
and by following a pre-published protocol (Normansell 2017).
The updated protocol was reviewed by a Cochrane Airways editor,
but it was not formally peer-reviewed.
Agreements and disagreements with other
studies or reviews
Our literature search identified only one systematic review com-
paring antibiotics with placebo for acute asthma exacerbations,
and that was the previous version of this Cochrane Review
(Graham 2001). This review found nothing significant to contra-
dict advice given in the BTS Guidelines for Asthma 2016 and the
GINA 2017 Guidelines, which recommend not giving antibiotics
routinely in acute asthma exacerbations (BTS/SIGN 2016; GINA
2017).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current guidelines suggest that antibiotics should not be routinely
prescribed for acute exacerbations of asthma. Overall, the find-
ings of this review support this position. We found limited evi-
dence that antibiotics given at the time of an asthma exacerbation
may lead to more symptom-free days at follow-up and may im-
prove PEFR at 10 days compared with standard care or placebo.
However, findings were inconsistent across the six heterogeneous
studies included in this review, we were able to perform very little
meta-analysis, two of the studies were conducted over 30 years
ago and most of the participants included in this review were re-
cruited from emergency departments. Therefore we have low con-
fidence in the effect estimates. Patient-important outcomes such
as hospital admission, length of stay, and further exacerbation in
the follow-up period were not reported, or evidence for these was
insufficient to permit conclusions. We were unable to rule out a
difference between groups in terms of all adverse events, and se-
rious adverse events were rare, with only 10 reported across three
trials.
Implications for research
A paucity of randomised evidence addresses the efficacy and safety
of antibiotics in the treatment of exacerbations of asthma. Recruit-
ment to any future trials may be hampered by prescribing of an-
tibiotics before presentation to trialists, as was experienced in the
recent UK trial. Furthermore, it would be considered unethical to
withhold antibiotics from an individual with a strongly suspected
bacterial infection, so it is unlikely that trials will be carried out in
this cohort, for whom antibiotics are already recommended.
Thus, future potential trialists should carefully weigh up the ben-
efits of further research in cohorts for whom antibiotics are not
currently recommended against the harms of antibiotic overuse.
If trials are carried out, trialists should provide details of base-
line asthma severity and presenting symptoms of participants re-
cruited to allow for identification of subgroups that may respond
differently to antibiotics. Stratification by objective inflammatory
marker measurement, such as serum CRP, would also be of in-
terest. Core outcome sets, including patient-important outcomes,
should be used to facilitate future meta-analysis. Adverse event
data should be carefully sought and reported.
A C K N OW L E D G E M E N T S
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Fonseca-Aten 2006
Methods Design: randomised double-blind placebo-controlled trial
Duration: trial endpoint of 5 days. Post-treatment follow-up carried out for 3 to 8 weeks
Setting: trial participants initially treated in an emergency department setting. Trial
carried out in the United States
Participants Population:43 childrenwith an acute exacerbationof asthmawere randomised to receive
clarithromycin (n = 22) or placebo (n = 21), in both cases in addition to normal care
Age: participants ranged in age from 4 to 15 years. Age range in the clarithromycin group
was 5 to 15 years, and age range in the placebo group was 4 to 15 years
Inclusion criteria: presentation for evaluation within 72 hours of the start of an acute
exacerbation of asthma
Exclusion criteria: children with diagnosed bacterial infection needing antibiotics; chil-
dren with contraindications to clarithromycin administration or with drug interactions
with clarithromycin; renal impairment; pregnancy; treatment with antibiotics or sys-
temic steroids within 2 weeks before presentation; chronic lung conditions (other than
asthma) or chronic systemic illnesses. Participants were also excluded following randomi-
sation if they did not attend follow-up visits 1 and 2 in the specified periods
Percentage withdrawn: withdrawal from the clarithromycin group was 36.4%; with-
drawal from the placebo group was 33.3%
Allowed medication: none recorded
Disallowed medication: none recorded
Interventions Clarithromycin group: participants received 15 mg/kg, in 2 divided doses, to a maxi-
mum of 500 mg twice daily for 5 days
Placebo group: participants received a placebo twice daily for 5 days. No further infor-
mation given
Outcomes Primary endpoints were comparison of nasal cytokine and chemokine concentrations,
and serum cytokines, between the 2 arms. The secondary endpoint was a comparison
between the 2 groups on the presence or absence of Chlamydia pneumoniae and My-
coplasma pneumoniae infection at each of the 2 follow-up visits
Notes Type of publication: peer-reviewed
Funding: study supported in part by grants fromAbbott Laboratories Inc and Children’s
Medical Centre of Dallas Research Advisory Committee
Contact: unsuccessful attempts made to contact study authors to seek further informa-
tion about clinical outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study authors described the study as ran-
domised but gave no further details
26Antibiotics for exacerbations of asthma (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fonseca-Aten 2006 (Continued)
Allocation concealment (selection bias) Unclear risk “Abbott Laboratories Inc (Abbott Park, IL)
provided formulations of clarithromycin
and placebo to theChildren’sMedical Cen-
ter at Dallas pharmacy for randomisation
and distribution to patients”
However, it is not clear if packs were iden-
tical, and if investigators would be able de-
termine assignment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study authors stated that it was a “double-
blind placebo controlled” study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific details were given regarding
outcome assessor blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk More than 50% of participants did not
complete follow-up; therefore status is un-
known
Selective reporting (reporting bias) High risk No prospective registration was identi-
fied, and not all evaluated outcomes were
reported numerically, e.g. “No clinical
differences were demonstrated for clar-
ithromycin therapy vs placebo on visit 3”
Other bias Low risk No other source of bias was identified
Graham 1982
Methods Design: randomised double-blind placebo-controlled trial
Duration: unclear
Setting: trial participants recruited on admittance to hospital. Trial carried out in the
United Kingdom
Participants Population: 60 adults with 71 exacerbations of asthma admitted to hospital between
February 1979 and December 1980. Participants were randomised to receive amoxicillin
(n = 37) or placebo (n = 34), in addition to normal care
Age: 13 to 82 years old. Mean age in the amoxicillin group was 41.2 years, with a range
from 13 to 82 years. Mean age in the placebo group was 37.4 years, with a range from
19 to 77 years
Inclusion criteria: admission to hospital with an acute exacerbation of asthma, with
FEV1 of 1.5 L or less, or PEFR of 150 L/min or less, or both, on admission
Exclusion criteria: participants whose chest X-rays showed signs of pneumonia; those
who had a penicillin allergy
Percentage withdrawn: 2 participants (5.9%) in the placebo arm withdrawn for ’slow
clinical progress’
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Graham 1982 (Continued)
Allowed medication: none recorded
Disallowed medication: none recorded
Interventions Amoxicillin group: 500 mg amoxicillin given 3 times daily, in addition to usual care
Placebo group: ’treated with identical placebos’
Outcomes Median length of hospital stay; physician assessment (scale of 4 to 12); participant
assessment (VAS); percentage predicted PEFR; percentage predicted FEV1; percentage
predicted FVC; days taken to reach 50% of final observed improvement (participant
and physician scores)
Notes Type of publication: peer-reviewed
Funding: not reported
Contact: no attempt made to contact study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no further de-
tails given
Allocation concealment (selection bias) Unclear risk No information given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as “double-blind placebo-con-
trolled”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific details given regarding outcome
assessor blinding. For patient-reported out-
comes, the risk is likely low, as the blinded
participant is the outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2patients dropped out of the placebo group
before discharge owing to slow clinical
progress, but trialists report including them
in a sensitivity analysis with the worst pos-
sible outcomes, and this had no impact on
overall results
Selective reporting (reporting bias) Unclear risk No prospective registration identified, but
all outcomes described in methods clearly
reported. Study authors used medians and
ranges and non-parametric tests, so data
could not be combined in meta-analyses
Other bias Unclear risk Participants could be included more than
once in the trial, as the episode, rather than
the individual, was the unit of randomisa-
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Graham 1982 (Continued)
tion: 60 participants experienced 71 exac-
erbations during the trial
Johnston 2006
Methods Design: randomised double-blind placebo-controlled trial
Duration: trial endpoint 10 days. Post-treatment follow-up carried out for 6 weeks
Setting: trial participants initially treated in an urgent care clinic, emergency room, or
in-patient hospital setting, and were then followed up after discharge at home. This was
a multi-centre, international study
Participants Population: 278 adults with acute exacerbations of asthma were randomised to receive
telithromycin (n = 134) or placebo (n = 136). In both cases, treatment was given in
addition to normal care
Age: 17 to 68 years old. Mean age in the telithromycin group was 39.5 years, with a
range from 17 to 64 years; mean age in the placebo group was 39.6 years, with a range
from 17 to 68 years
Inclusion criteria: adults between 18 and 55 years of age with a diagnosis of asthma
for over 6 months, who sought medical help for an acute exacerbation of asthma, were
enrolled within 24 hours after presentation. Inclusion criteria included increased wheeze
and dyspnoea, with PEF < 80% of predicted value; ability to complete a diary of asthma
symptoms and perform a home test of PEF; and ability to give written informed consent
Exclusion criteria: need for immediate intensive care; known allergic cause of the acute
episode; known lower respiratory tract disease, apart from asthma; smoking history of
10 or more pack-years; need for use of regular OCS; use of any antibiotic within 30 days
before enrolment; obvious infection requiring antibiotic treatment
Percentage withdrawn:withdrawal from the telithromycin group was 5.97%, and with-
drawal from the placebo group was 5.15%
Allowedmedication: participants were able to continue their usual treatment for asthma
during the study. Participants who began taking an additional ICS within 3 days before
or after the exacerbation received a dose increase at the investigator’s discretion; those
who required OCS for the exacerbation were prescribed prednisolone at 30 mg/d for 7
days
Disallowed medication: none recorded
Interventions Telithromycin group: 800 mg telithromycin a day, given orally in the form of two 400-
mg capsules once daily for 10 days, in addition to usual care
Placebo group: 2 placebo capsules, identical to telithromycin capsules, given once daily
in addition to usual care
Outcomes Primary outcomes were change from baseline asthma symptom scores and PEFR in the
morning over the 10-day treatment period, using daily diaries of participants. Asthma
symptoms were measured by a modified diary card symptom score in which participants
rated their symptoms on a 7-point scale (with 0 meaning no symptoms and 6 meaning
severe symptoms). Clinic pulmonary function tests were secondary outcomes
Notes Type of publication: peer-reviewed
Funding: industry: Sanofi-Aventis. “All authors had full access to the data, and no limits
were placed by the study sponsor with respect to statements made in this report”
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Johnston 2006 (Continued)
Contact: trial lead author contacted for additional methodological details and outcome
data; response received in September 2017
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk On a centrally randomised basis with use
of computer-generated codes, participants
were assigned in a 1:1 ratio
Allocation concealment (selection bias) Low risk On a centrally randomised basis with use
of computer-generated codes, participants
were assigned in a 1:1 ratio
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were assigned in a 1:1 ratio to
receive oral telithromycin (two400mgcap-
sules daily) or placebo (2 capsules identi-
cal in appearance) for 10 days. Correspon-
dence with lead author confirmed all par-
ticipants, trial personnel, and outcome as-
sessors were masked throughout
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No specific details were given in the trial
report regarding outcome assessor blind-
ing. Correspondence with lead author con-
firmed that all participants, trial person-
nel, and outcome assessors were masked
throughout
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Almost all participants were included in the
safety analysis. Dropout overall was reason-
ably balanced, although more participants
withdrew from the intervention arm owing
to adverse events (8 vs 3), and more from
the placebo arm owing to lack of efficacy
(2 vs 0). More data for symptom score and
PEFR were missing
Selective reporting (reporting bias) Unclear risk Several outcomes (health status at follow-
up (6 weeks); need for additional medica-
tions (e.g. ICS, OCS, bronchodilator use);
time to next acute exacerbation of asthma)
listed in the prospective trial registration
were not fully reported. The lead author
provided the following explanation: “the
time-to-next-acute-exacerbation and need
for additional medications data were not
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Johnston 2006 (Continued)
includedbecause acquisition of such data in
the setting of an acute exacerbation study,
not unexpectedly, was so incomplete that a
decision was taken not to analyse them”
Other bias Low risk No other source of bias was identified
Johnston 2016
Methods Design: randomised double-blind placebo-controlled trial
Duration: trial endpoint 10 days. Post-treatment follow-up carried out for 6 weeks
Setting: multi-centre study based in the United Kingdom. Participants recruited from
30 secondary care hospitals and 1 primary care centre
Participants Population: 199 adults with an acute exacerbation of asthma were randomised to receive
azithromycin (n = 97) or an identical placebo (n = 102), both in addition to normal care.
Participants were recruited at a wide range of hospitals across the United Kingdom
Age:mean age of participants in the azithromycin arm of the study was 39.1 years; mean
age of those in the placebo arm was 36.2 years
Inclusion criteria: adults aged 18 to 55 with any smoking history, aged 56 to 65 with
less than a 20 pack-year smoking history, or older than 65 with a less than 5 pack-year
smoking history, with a documented history of having asthma for over 6 months and
recruitment within 48 hours of presentation to medical care with an acute deterioration
in asthma control requiring a course of oral or systemic corticosteroids or both, and PEF
or FEV1 < 80% of predicted value
Exclusion criteria: use of oral or systemic antibiotics within 28 days before enrolment;
need for intensive care; significant lung disease other than asthma; long-term use of over
20 mg of OCS daily; known QT-interval prolongation; history of bradyarrhythmias or
tachyarrhythmias or uncompensated heart failure; taking drugs known to prolong QT
interval
Percentage withdrawn: withdrawal from the azithromycin group was 10.3%, and with-
drawal from the placebo group was 12.7%
Allowed medication: none recorded
Disallowed medication: none recorded other than those listed in the exclusion criteria
Interventions Azithromycin group: 2 x 250 mg azithromycin capsules taken once daily for 3 days, in
addition to normal care
Placebo group: placebo identical in appearance to azithromycin treatment given once
daily, in addition to normal care
Outcomes Primary outcomewas diary card summary symptom score. Secondary outcomes included
quality of life, measured by the acute AQLQ and the mini AQLQ; pulmonary function
tests including FEV1, FVC, FEV1/FVC, FEF, FEF50, PEF and time to 50% reduction
in symptom score
Notes Type of publication: peer-reviewed
Funding: “This study was funded by the Efficacy and Mechanisms Evaluation pro-
gramme of theMRC, in partnership with theNIHR (Funders Reference No. 10/60/27).
The trial was supported by theNIHRComprehensive Biomedical ResearchCentre based
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Johnston 2016 (Continued)
at Imperial College Healthcare NHS Trust and Imperial College London. Dr Johnston
is an NIHR senior investigator and was supported by European Research Council FP7
Advanced Grant 233015, a Chair from Asthma UK (CH11SJ), and MRC Centre grant
G1000758. The funders’ had no role in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; preparation, review, or approval
of the manuscript; and decision to submit the manuscript for publication”
Contact: trial lead author contacted for additional methodological details and outcome
data; response received in September 2017
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was web based via access
to a secure Imperial College London server
and was performed using the InForm ITM
System. Randomisation lists were gener-
ated by an ICTU statistician. Details such
as block size were kept confidential and
held separately by the ICTU
Allocation concealment (selection bias) Low risk The identity of study medications was
blinded and medications were packaged
and supplied by Sharp Clinical Services
(Crickhowell, UK) with code-break en-
velopes. Overencapsulated azithromycin
capsules and placebo capsules were placed
into child-resistant tamper-evident con-
tainers, and a randomised label applied to
each container
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk This was a double-blind trial; therefore, all
participants and care providers and those
assessing outcomes were blinded to study
treatment. Members of the trial teamman-
aging and analysing the datawere also blind
to the treatment received. Researchers im-
posed no requirement for unblinding dur-
ing the AZALEA study; therefore no par-
ticipants were unblinded before statistical
analysis took place
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk This was a double-blind trial; therefore, all
participants and care providers and those
assessing outcomes were blinded to study
treatment. Members of the trial teamman-
aging and analysing the datawere also blind
to the treatment received. Researchers im-
posed no requirement for unblinding dur-
32Antibiotics for exacerbations of asthma (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Johnston 2016 (Continued)
ing the AZALEA study; therefore no par-
ticipants were unblinded before statistical
analysis took place
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All participants were included in the safety
analysis, but only 80% of participants at-
tended all 4 study visits and some data for
symptom score and PEFR are missing
Selective reporting (reporting bias) Low risk Prospectively registered trial; outcomes re-
ported as planned
Other bias Low risk No other source of bias identified
Koutsoubari 2012
Methods Design: randomised open-label study
Duration: trial endpoint 21 days. Post-treatment follow-up carried out for 12 weeks
Setting: participants recruited from the population of patients of the AllergyDepartment
of the 2nd Pediatric Clinic at the University of Athens, Greece. They were treated in the
hospital, then discharged home or continued in hospital according to their clinical needs
Participants Population: 40 children with acute exacerbations of asthma were randomised to receive
clarithromycin (n = 18), in addition to normal care, or to receive just normal care (n =
22)
Age: children aged 6 to 14 participated in the study. Mean age of participants in the
clarithromycin arm was 9.1 years, and mean age of those in the control arm was 8.4 years
Inclusion criteria: children given a diagnosis of intermittent or mild persistent asthma,
from the population followed up in the Allergy Department, 2nd Pediatric Clinic at the
University of Athens, were invited to participate. If they experienced an acute asthma
exacerbation, according to the judgement of their parents, with confirmation by the
study physician, and wished to participate, they were included in the study
Exclusion criteria: any additional chronic condition, apart from allergic rhinitis; chil-
dren unable to follow study procedures
Percentage withdrawn: percentage of participants withdrawn was 0% in both arms of
the study
Allowed medication: none recorded
Disallowed medication: none recorded
Interventions Clarithromycin group: participants received 15 mg of clarithromycin per kg of body
weight once daily for 3 weeks, plus normal care
Control group: participants received just normal care
Outcomes Primary outcome was symptom-free days during the 12-week follow-up period. Sec-
ondary outcomes were number and severity of periods with loss of asthma control, time
to loss of control, duration and severity of the index exacerbation, PEFR variability, and
lung function during the follow-up period
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Koutsoubari 2012 (Continued)
Notes Type of publication: peer-reviewed
Funding: none recorded
Contact: no attempt made to contact study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computerized randomisation table,
blinded to patients and to the study physi-
cian, was used to allocate children” to study
arms
Allocation concealment (selection bias) Low risk “A computerized randomisation table,
blinded to patients and to the study physi-
cian, was used to allocate children” to study
arms
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was an open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk This was an open-label study
Incomplete outcome data (attrition bias)
All outcomes
Low risk “In fact, no patient/parent dropped out of
the study after randomisation”
Selective reporting (reporting bias) Unclear risk No prospective registration was identified,
but all outcomes described in the methods
were clearly reported. Study authors used
medians and interquartile ranges for non-
normal data, so these could not be com-
bined in meta-analyses
Other bias Low risk No other source of bias identified
Shapiro 1974
Methods Design: randomised double-blind placebo-controlled trial
Duration: trial endpoint 7 days; post-treatment follow-up lasted between 1 and 3 weeks,
varying between participants
Setting: study carried out at the Children’s Orthopedic Hospital and Medical Center,
in Seattle, Washington, USA, between September 1971 and July 1972
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Shapiro 1974 (Continued)
Participants Population: 50 children with acute exacerbations of asthma were recruited. They were
randomised to receive hetacillin (n = 20) or placebo (n = 24), both in addition to normal
care
Age: age range of study participants was from 1 to 18 years
Inclusion criteria: children admitted to this study were hospitalised at Children’s Or-
thopedicHospital andMedical Center between September 1971 and July 1972 for status
asthmaticus. This was considered to be a lack of response of severe bronchospasm to 3
subcutaneous injections of 1:1000 aqueous epinephrine given at 15-minute intervals
Exclusion criteria: evidence of bacterial disease, specifically any of the followingfindings:
otitis media, purulent pharyngitis, or fever; lobular pulmonary infiltrate on admission
chest X-ray; recent receipt of antibiotics
Percentage withdrawn: 6 excluded - 3 because they developed signs and symptoms
suggesting bacterial disease, and 3 others because of failure to administer the study
preparation (hetacillin or placebo). This gives an overall withdrawal percentage of 12%
Allowedmedication: all participants were treated via the same protocol, which included
intravenous fluid, aminophylline, oral theophylline compounds, hydrocortisone, oral
prednisone, nebulised isoproterenol, and phenylephrine and oxygen
Disallowed medication: none recorded, aside from recent use of antibiotics as men-
tioned in the exclusion criteria
Interventions Hetacillin (ampicillin) group: 100 mg/kg/24 h IV followed after 24 hours by 225 mg
oral 4 times daily for 6 days
Placebo group: identically packaged to hetacillin and administered on the same schedule
Outcomes Hospital follow-up evaluation: (a) vital signs (pulse, respirations, blood pressure) at least
every hour for 12 hours, then as desired by house officer; (b) pulmonary index at 1, 12,
24 hours; (c) FVC and FEV1 at 1, 12, and 24 hours when possible; (d) chest X-rays and
blood gases repeated as needed. Follow-up after discharge: visit to private physician or
allergy clinic scheduled 1 to 3 weeks after discharge, so information on medications and
complications, physical examination, pulmonary function tests, and convalescent serum
could be obtained
Notes Type of publication: peer-reviewed
Funding: supported in part by Public Health Service training grant S-TO1-A10011
from the National Institute of Allergy and Infectious Disease, and in part by a grant
from Bristol Laboratories
Contact: no attempt made to contact study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as ’pre-randomised’,
but no further details were given
Allocation concealment (selection bias) Unclear risk Study was described as ’pre-randomised’,
but no further details were given
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Shapiro 1974 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study authors stated that it was ’double-
blind placebo-controlled’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific details were given regarding
outcome assessor blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Fifty asthma admissions were initially in-
cluded in the study. Six were excluded - 3
because of development of signs and symp-
toms suggesting bacterial disease, and 3
because of inadvertent failure to admin-
ister the study preparation (hetacillin or
placebo). Distribution between study arms
of those excluded because of suspected bac-
terial infection and because of protocol vi-
olations is not reported
Selective reporting (reporting bias) High risk No prospective registration was identified.
Not all evaluated outcomes were reported
numerically so they could not be included
in meta-analysis (e.g. graphically displayed
only)
Other bias Unclear risk Baseline imbalance between arms was de-
tected including difference in mean num-
ber of days of wheezing before admission
(2.6 in hetacillin group; 5.8 in placebo
group)
AQLQ: asthma quality of life questionnaire; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; FEF: forced
expiratory flow; FEF50: forced expiratory flow at 50% expiration; ICS: inhaled corticosteroids; MRC: Medical research Council;
NIHR: National Instiutute for Health Research; OCS: oral corticosteroids; PEF: peak expiratory flow; PEFR: peak expiatory flow
rate; QT: QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart’s electrical
cycle; VAS: visual analogue scale.
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Anonymous 2002 Commentary on a study of long-term prophylactic antibiotic use
Anonymous 2009 German commentary on a study of long-term prophylactic antibiotic use
Cameron 2013 Study of long-term prophylactic antibiotic use in adult smokers with asthma
Hahn 2004 Study of long-term prophylactic antibiotic use
Hahn 2011 Study of long-term prophylactic antibiotic use
Lewis-Faning 1960 Study of long-term prophylactic antibiotic use
NCT00266851 Study of long-term prophylactic antibiotic use
Simpson 2007 Study of long-term prophylactic antibiotic use
Stokholm 2016 Study involved young children (aged 1 to 3 years) with asthma-like symptoms (i.e. without a diagnosis of
asthma). Wheeze in this age group generally is not considered to be the same entity as asthma
Sumpaico 1991 Study involved children with chronic rather than acute asthma
Wang 2012 Study of long-term prophylactic antibiotic use
Characteristics of studies awaiting assessment [ordered by study ID]
EUCTR2010-018592-16-DK
Methods Randomized controlled study within the ABC cohort (Asthma Begins in Childhood)
Participants Participants in the ABC cohort study. Resident of Copenhagen, Sjælland, Møn, Lolland, or Falster. Both parents
are Danish-speaking. Parents agree to enrol the child. The child is at least 1 year old and has had 1 of the following
asthma symptoms: 5 episodes within 6 mdr (1 episode: 3 consecutive days with lower airway symptoms) or 4 weeks
daily lung symptoms or acute severe asthma
Interventions Intervention: azithromycin (oral suspension, 40 mg/mL)
Control: placebo oral suspension, same volume as active drug
Outcomes Primary endpoint(s)
• Changes in symptom score from day 1 until termination of each asthmatic episode during the age of 1 to 3
years
• Duration of each asthmatic episode
Secondary endpoint(s): no secondary endpoints
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EUCTR2010-018592-16-DK (Continued)
Notes Study Title: antibiotics as a treatment of repeated asthmatic symptoms in children - a randomised, controlled study
within the ABC cohort (Asthma Begins in Childhood)
Date of first registration: 04/10/2010; last refreshed: 20/09/2016, with status currently no longer recruiting
Registered on EU clinical trial register
No contact details available
Characteristics of ongoing studies [ordered by study ID]
NCT02003911
Trial name or title Azithromycin for children hospitalised with asthma
Methods Randomised controlled trial; double-blind parallel-group
Participants Children aged 4 to 12 years, with admission diagnosis of asthma at the Children’s Hospital at Montefiore and
history of persistent asthma (as defined by National Heart, Lung, and Blood Institute)
Interventions Intervention: azithromycin suspension at 10 mg/kg/dose (max 500 mg), once daily for 3 days
Control: placebo suspension, same volume as active drug once daily for 3 days
Outcomes Primary outcome
• Length of hospital stay
Secondary outcomes
• Readmission rate
• Number of hospital readmissions for asthma
• Days of school missed by participant
• Days of work missed by parent/guardian
• Number of emergency room visits for asthma symptoms
• Number of physician office visits for asthma symptoms
• Number of recurrences of asthma symptoms
• Number of courses of oral steroids
Starting date October 2013
Contact information Lindsey C Douglas, MD
Division of Hospital Medicine, Assistant Professor, Albert Einstein College of Medicine, Montefiore Medical
Center, New York, United States
douglas@montefiore.org
Notes Study currently recruiting participants. Information last verified May 2017
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D A T A A N D A N A L Y S E S
Comparison 1. Antibiotics versus placebo/usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom score 2 Mean Difference (Fixed, 95% CI) -0.34 [-0.60, -0.08]
1.1 Adults 2 Mean Difference (Fixed, 95% CI) -0.34 [-0.60, -0.08]
1.2 Children 0 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
2 All adverse events 3 506 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.69, 1.43]
2.1 Adults 2 462 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.69, 1.45]
2.2 Children 1 44 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.12, 5.18]
3 Serious adverse events 3 502 Risk Difference (M-H, Fixed, 95% CI) 0.00 [-0.03, 0.03]
3.1 Adults 2 462 Risk Difference (M-H, Fixed, 95% CI) 0.00 [-0.03, 0.03]
3.2 Children 1 40 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.09, 0.09]
4 Length of hospital stay (days) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Adults 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Children 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 PEF (GIV) 2 Mean Difference (Fixed, 95% CI) 23.42 [5.23, 41.60]
5.1 Adults 2 Mean Difference (Fixed, 95% CI) 23.42 [5.23, 41.60]
5.2 Children 0 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
6 PEF 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Adults 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Children 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
A D D I T I O N A L T A B L E S
Table 1. Summary of included studies
Study ID Total n Country Age range (years) Duration of follow-
up
Intervention compar-
ison
Fonseca-Aten 2006 43 USA 4-15 3-8 weeks Clarithromycin (15
mg/kg) vs placebo
Graham 1982 71 UK 13-82 Unclear Amoxicillin (300 mg 3
days) vs placebo
Johnston 2006 278 International (multi-
centre)
17-68 6 weeks Telithromycin (800
mg/d) vs placebo
Johnston 2016 199 UK Mean (SD) = 39.9 (14.
82)
6 weeks Azithromycin (500
mg/d) vs placebo
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Table 1. Summary of included studies (Continued)
Koutsoubari 2012 40 Greece 6-14 12 weeks Clarithromycin
(15 mg/kg/d for 3/52)
vs placebo
Shapiro 1974 50 USA 1-18 7 days and 1 to 3 weeks Hetacillin (ampicillin
100mg/kg/24 h IV fol-
lowed by 900 mg PO/
d for 6/7) vs placebo
WH A T ’ S N E W
Last assessed as up-to-date: 17 October 2017.
Date Event Description
17 October 2017 New citation required and conclusions have changed New review author team. We updated the proto-
col including the background, PICO, and methods
(Normansell 2017). Review title edited
17 October 2017 New search has been performed New literature search run
H I S T O R Y
Protocol first published: Issue 3, 2000
Review first published: Issue 2, 2001
Date Event Description
16 June 2008 Amended Converted to new review format
29 December 2000 New citation required and conclusions have changed Substantive amendments made
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C O N T R I B U T I O N S O F A U T H O R S
Normansell R - drafted revised protocol, screened references, extracted data, performed data entry and analysis, drafted results, drafted
summary of findings table, drafted discussion, drafted conclusions.
Waterson S - drafted revised protocol, screened references, extracted data, drafted discussion.
Dennett EJ - drafted revised protocol, screened references, drafted summary of findings table, drafted abstract and plain language
summary.
Dunleavy A - contributed to protocol revision, drafted discussion.
Sayer B - drafted revised protocol, screened references, extracted data, drafted discussion.
Del Forno M - contributed to protocol revision, commented on draft review.
Previous version of review
Vanessa Graham - lead author, protocol development, study selection, quality assessment, data extraction, data analysis, text of review.
Toby Lasserson - protocol development, study selection, quality assessment, data extraction, data analysis, text of review.
Brian Rowe - protocol development, review write-up, assigned ARG editor.
D E C L A R A T I O N S O F I N T E R E S T
Current version:
BS: none known.
EJD: Managing Editor of Cochrane Airways.
RN:Co-ordinating Editor of Cochrane Airways and employed by anNIHRprogramme grant. RN is also a qualified general practitioner.
SW: none known.
MDF: none known.
AD: none known.
Previous version: The authors who have been involved in this review have done so without any known conflicts of interest. One of the
review authors was involved with one of the primary studies (Graham 1982). However, none of the review authors are considered paid
consultants to any pharmaceutical companies that produce antibiotic agents.
S O U R C E S O F S U P P O R T
Internal sources
• Division of Emergency Medicine, University of Alberta, Edmonton, AB, Canada.
• NHS Research and Development, UK.
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External sources
• Garfield Weston Foundation, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This review is an update of a previous review (Graham 2001), and we ran a new ’all years’ search.We fully revised the protocol including
background, PICO (population, intervention, comparison, outcomes), and methods and registered it on PROSPERO (Normansell
2017).
Changes include the following.
1. Prepared by new review author team.
2. Redrafted background.
3. Updated PICO.
i) Clarified ’types of studies’ to be parallel or cluster-randomised controlled trials (RCTs) and excluded cross-overs.
ii) Broadened ’types of participants’ to be recruited from primary care and outpatient and inpatient clinics, as well as the
emergency department.
iii) Excluded trials of people with other respiratory diagnoses.
iv) Clarified to exclude prophylactic antibiotics, although this did not change the intent of the original review.
v) Changed the outcomes.
4. Updated the methods.
i) Updated search strategy in line with Cochrane Airways Review Group best practice.
ii) Updated all other methods in line with Cochrane MECIR standards and using standard text from the Cochrane Airways
Review Group prepared protocol.
iii) Added ’summary of findings’ table for all outcomes included in the review.
iv) Specified new subgroup and sensitivity analyses.
v) Updated to new risk of bias tool.
5. Re-extracted data from all previously included studies.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Disease; Age Factors; Anti-Bacterial Agents [∗therapeutic use]; Asthma [∗drug therapy]; Randomized Controlled Trials as Topic
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MeSH check words
Adult; Child; Humans
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